Esomeprazole and Radiation Induced Esophagitis
Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 14, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Rush University Medical Center
- Interventions being studied
- Drug: Esomeprazole 40 mg
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patient is ≥ 18 years of age.
- Patient or patient's legal representative is willing and able to provide written informed consent and HIPAA authorization prior to performance of any study related activity.
- Patient is willing and able to comply with scheduled visits and treatment schedules.
- Patient has histopathologically confirmed diagnosis of NSCLC clinical stage III (as per the 8th edition of American Joint Committee on Cancer Staging).
- Patients will receive thoracic radiation with estimated maximum dose to esophagus of at least 30 Gy (EQD2) in combination with concomitant chemotherapy.
- Patient has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
- Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine HCG) within 2 weeks of enrollment).
- Double inclusion in any ongoing trial (if the other trial permits) will be allowed.
- Patient has history of gastroesophageal junction or stomach cancer.
- Patient has history of pre-existing severe or very severe dysphagia.
- Patient has history of severe liver disease, acute or subacute systemic lupus erythematosus.
- Patient has interstitial nephritis.
- Patient has history of peptic ulcer disease.
- Patient has prior history of upper gastrointestinal bleeding.
- Patient has a history of thoracic radiotherapy within 2 years of enrollment.
- Patient has known or suspected allergic response and prior adverse drug reaction with proton pump inhibitors.
- Patient is currently on clopidogrel, nelfinavir, rilpivirine, methotrexate, rifampin, digoxin, tacrolimus, or phenytoin as these may have major drug interaction with esomeprazole.
- Patients without concomitant chemoradiotherapy and with estimated maximum dose to esophagus of less than 30 Gy (EQD2).
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Rush University Medical CenterChicago, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 14, 2026. Always confirm current availability with the study team.